Concise Review: Therapeutic Potential of the Mesenchymal Stem Cell Derived Secretome and Extracellular Vesicles for Radiation-Induced Lung Injury: Progress and Hypotheses

SIGUANG XU a, CONG LIU a, HONG-LONG JI b,c

Key Words. Mesenchymal stem cells • Secretome • Exosome • Radiation pneumonitis • Lung fibrosis

ABSTRACT

Radiation-induced lung injury (RILI) is a common complication in radiotherapy of thoracic tumors and limits the therapeutic dose of radiation that can be given to effectively control tumors. RILI develops through a complex pathological process, resulting in induction and activation of various cytokines, infiltration by inflammatory cells, cytokine-induced activation of fibroblasts, and subsequent tissue remodeling by activated fibroblasts, ultimately leading to impaired lung function and respiratory failure. Increasing evidence shows that mesenchymal stem cells (MSCs) may play a main role in modulating inflammation and immune responses, promoting survival and repair of damaged resident cells and enhancing regeneration of damaged tissue through soluble paracrine factors and therapeutic extracellular vesicles. Therefore, the use of the MSC-derived secretome and exosomes holds promising potential for RILI therapy. Here, we review recent progress on the potential mechanisms of MSC therapy for RILI, with an emphasis on soluble paracrine factors and MSC-released exosomal miRNAs. Hypotheses on how MSC derived exosomes or MSC-released exosomal miRNAs could attenuate RILI are also proposed. Problems and translational challenges of the therapies based on the MSC-derived secretome and exosomes are further summarized and underline the need for caution on rapid clinical translation.

INTRODUCTION

Radiotherapy is an effective and important strategy for cancer treatment that may extend the survival time of patients by improving localized inhibition of tumor development [1]. However, radiation-induced lung injury (RILI) is a common adverse effect, with a lethality of up to 15%, and limits the therapeutic dose of radiation that can be administered to control tumors [2]. RILI is a complex pathological process, resulting in an early radiation pneumonitis (RP) and late radiation-induced lung fibrosis (RLIF) [2]. Symptomatic RP occurs in ~5%–50%, ~5%–10%, and ~1%–5% of patients irradiated for cancers of the lung, mediastinal lymphatics, and breast, respectively [3, 4]. Pneumonitis is characterized by shortness of breath, cough, and fever; however, patients with severe RP have almost 50% mortality [5]. RLIF is a chronic, progressive, and fatal interstitial pulmonary disease with a poor prognosis, and poor response to available medical therapies [6]. The rate of RLIF, which can continue to evolve around 1 year after radiotherapy, is reportedly up to 70%–80% in regions that use high-dose radiotherapy [7]. Therefore, RILI has become a focus of prevention and treatment in biomedical research.

Currently, RP can be treated with steroids but abrupt withdrawal may activate latent injury to the lung [8]. Amifostine (WR-2721) remains...
the only agent currently in clinical use as a radioprotector, which can scavenge free radicals, protect DNA, and accelerate repair [9]. However, the radioprotective effects of chemical compounds, including amifostine, are short-term, and associated with side effects such as nausea, vomiting, diarrhea, and hypotension [10, 11], thereby limiting their clinical use. The biological growth factors and cytokines such as IL-7, IL-11, granulocyte-colony stimulating factor, macrophage-colony stimulating factor, and keratinocyte growth factor have been used to alleviate radiation-induced damage. However, success with these compounds has also been limited [11]. Lycopene, as a naturally occurring dietary carotenoid, can protect against γ-radiation induced DNA damage and antioxidant status in rats [12]. However, there are still key considerations that need to be addressed in evaluating a potential antioxidant. Similarly, the signaling inhibitors, including TLR agonists CBLB502 and the STAT3 signaling inhibitor WP1066, can alleviate RP, but their toxicity and side effects still need to be considered before clinical application [9, 13]. In addition, although lung transplantation is the most useful intervention for treating RILF, it is limited by the lack of available donated lungs and transplantation-related complications [14, 15].

Therefore, a new and more effective therapeutic strategy based on the pathological mechanisms of RILI is urgently needed. Mesenchymal stem cells (MSCs), as a population of multipotent stem cells, can modulate the inflammation response, promote survival and repair of damaged resident cells, and enhance regeneration of damaged tissue [16], and thus show potential for clinical utility. Moreover, their advantages include convenient isolation and culture, low immunogenicity, regenerative and multiple differentiation abilities, and potent immunosuppressive effects [17–22]. These beneficial properties make MSC therapy a promising candidate for the treatment of RILI. Although preclinical studies showed therapeutic effects of MSCs for RILI therapy [23], many hurdles still exist for translating the therapeutic promise of MSCs in preclinical studies to the clinical setting [24, 25]. To overcome those concerns of MSC-based therapy, several studies showed that MSC-derived conditioned medium (CM) recapitulated many of the therapeutic properties of the parent cells, suggesting that the development of cell-free strategies based on using components of MSC-derived CM, such as soluble factors, and extracellular vesicles, such as exosomes, merits further investigation [25, 26]. Indeed, accumulating evidence shows that the therapeutic effects of MSCs are due to their capacity to secrete paracrine factors [26–28]. In this review, we have summarized the potential mechanisms underlying MSC therapy for radiation-induced pulmonary events in the lungs, with an emphasis on the importance of specific secreted soluble paracrine cytokines. Additionally, based on currently published data, we have predicted a potential therapeutic role for miRNAs shuttled by exosomes from MSCs. These data may help to support the therapeutic strategy of using the MSC-derived secretome and exosomes to treat RILI and to accelerate this strategy from bench to bedside.

**THE POTENTIAL OF MSC THERAPY FOR RILI BASED ON THE SECRETION OF SOLUBLE FACTORS**

**Modulation of Expression Levels of Inflammatory and Fibrotic Cytokines**

For decades, the biologic response to radiation has been reported to start with the generation of reactive oxygen species (ROS) [29]. Similarly, RILI, as a radiation-associated pulmonary complication, is different from other types of acute lung injury because it starts with radiation-induced energy deposition and the generation of ROS, followed by a series of biologic responses, including a cascade of subsequent inflammatory events, angiogenesis, programmed cell death, autophagy, production of extracellular matrix, and crosstalk of activated signal transduction pathways, ultimately leading to lung fibrosis and respiratory failure [3, 30, 31]. In this process, the release of various cytokines is considered to play a major role in the pathogenesis of RILI [30, 32, 33], including proinflammatory cytokines such as interleukin-1α (IL-1α), IL-1β, IL-6, and profibrogenic cytokines such as transforming growth factor β1 (TGF-β1). Indeed, MSCs have been reported to inhibit ROS and reduce oxidative stress, playing an antioxidant role and reducing proinflammatory responses by regulating the release of various cytokines in many experimental models [34–37]. Moreover, increasing evidence suggests that gene-modified MSCs or MSC-expressed cytokines play a key role in activating anti-inflammatory and antifibrotic signaling or neutralizing proinflammatory and profibrotic cytokines via secreting paracrine cytokines, superoxide dismutases, or soluble inflammatory cytokine receptors. These activities may aid in repairing damaged lung tissue and in tissue regeneration following RILI.

**Inhibition of Lung Myofibroblasts by MSC Secretion of Hepatocyte Growth Factor and Prostaglandin E2**

Radiation can stimulate lung fibroblasts to secrete cytokines, undergo hyperplasia, and differentiate into myofibroblasts [38–40]. Myofibroblasts can further promote the synthesis of additional collagens, leading to excessive deposition and abnormal remodeling of the extracellular matrix, which is a hallmark of RILI [39–41]. Zhang et al. reported that human umbilical cord MSCs (hucMSCs) can attenuate RILI by inhibiting myofibroblastic differentiation of human lung fibroblasts [42]. However, whether the inhibition involves the secretome of MSCs was unclear. Dong et al. further showed that human adipose tissue-derived MSCs can downregulate levels of TNF-α and TGF-β1 by stimulating secretion of hepatocyte growth factor (HGF) and prostaglandin E2 (PGE2) [43].

Endogenous HGF/c-Met signaling plays important roles in tissue repair [44], and the expression of HGF and c-Met can be upregulated by exogenous stimuli such as MSCs and gene-modified MSCs [45]. MSC-secreted HGF probably attenuates EMT in type II AECs by increasing intracellular levels of Smad7 upon binding to c-Met and by upregulating the expression of matrix metalloproteinases-1, -3, and -9 in injured sites in a PI3K/Akt/p70-dependent manner, thereby promoting apoptosis of myofibroblasts [46–48]. Wang et al. further showed that HGF-modified MSC therapy can increase endogenous HGF/c-Met expression in a mouse RILI model [49]. S1P/S1PR1 may also participate in the HGF/c-Met-mediated process [49–51], suggesting that HGF-modified MSCs may exert anti-inflammatory and antifibrotic effects via paracrine secretion of HGF.

The cytokine PGE2 is secreted by MSCs to reprogram host macrophages to increase their anti-inflammatory IL-10 production [52]. Moreover, PGE2 can inhibit TGF-β1-induced activation and fibroblast proliferation, thereby reducing the production of the fibrosis marker α-SMA and collagen by elevating intracellular cAMP levels, and PGE2 also induces apoptosis in myofibroblasts by increasing the activity of the PTEN...
protein, which blocks the PI3K/Akt signaling pathway [53–58]. These findings suggest the potential application of MSCs in RILI therapy via activation of anti-inflammatory pathways and inhibition of profibrotic signaling in a paracrine factor-associated manner.

**Protection of Injured Cells against ROS by MSC Secretion of Superoxide Dismutases**

RILI starts with radiation-induced energy deposition and generation of ROS [3, 30, 31]. Inflammatory diseases are also accompanied by excessive production of ROS and depletion of endogenous antioxidants, but antioxidant enzymes such as superoxide dismutase 1 (SOD1, Cu/Zn SOD) are known to be very effective scavengers of ROS [59]. It was reported that MSC-secreted SOD1 protected lungs from radiation-induced endothelial cell damage [60]. Similarly, SOD3 or manganese superoxide dismutase-modified MSCs also have more anti-inflammatory and antifibrotic effects on RILI, compared with nongene-modified MSCs [61, 62]. This effect of superoxide dismutase is probably based on their ability to catalyze the dismutation of the superoxide radical into oxygen and hydrogen peroxide, thereby protecting injured cells against RILI generated during RILI [29, 35, 63, 64].

**MSC Secretion of Soluble Factors that Inhibit Proinflammatory Signaling and Immune Cell Activation**

Expression levels of the key proinflammatory cytokines IL-1 and TNF-α in the lung correlate with the development of pulmonary injury in rodents exposed to radiation [33, 65]; however, MSC-secreted interleukin 1 receptor antagonist (IL1RN) can function as a competitive inhibitor of IL-1α and IL-1β, and block the production and/or activity of TNF-α and IL-1α signaling in lung tissue [66], suggesting the possibility of using MSC-secreted IL1RN as a paracrine mediator for treating RILI. Moreover, increased NF-κB activity often triggers inflammation-related pathologies including RILI [67], but Yagi et al. reported that human MSCs can neutralize TNF-α by secreting significant quantities of soluble TNF receptor 1, which consequently blocks activation of NF-κB by TNF-α [68]. Such neutralization of TNF-α would contribute to the anti-inflammatory effect of MSC therapy on TNF-α/NF-κB signaling in RILI via a paracrine manner. A similar effect was found in TGF-β type II receptor-modified MSCs and MSC-conditioned medium [26, 69]. Notably, Xue et al. reported that only 0.1% of lung cells are derived from transplanted MSCs, a level too low to support the observed protective effects. Other studies have also reported that MSCs can repair injured lung tissues without significant engraftment or differentiation in some situations [26, 70], suggesting that other factors, including paracrine cytokines (Table 1), may be mainly involved in regulating anti-inflammatory responses and repair mechanisms.

Like infectious, thermal, or physical damage, radiation-induced damage of lung tissue can lead to the activation of the immune system [60]. Infiltration of innate and adaptive immune cells is a common response of normal tissues to ionizing radiation in the lung [71]. The pneumonitic phase is characterized by the recruitment of immune cells and a subsequent cascade of cytokines/chemokines that results in various degrees of lung inflammation after ionizing radiation [71]. MSCs not only have a reparative and regenerative ability via the secretion of paracrine cytokines, including EGF, FGF, PDGF, TGF-β, VEGF, HGF, Ang-1, KGF, SFDF-1, IGFB-1, and others [72], but also have immunosuppressive properties through the secretion of IL-10, TSG6, IL-6, LIF, PGE2, HO-1, and other cytokines [72]. These immunosuppressive cytokines can minimize organ damage caused by inflammation and cells activated by the immune system via inhibiting activation and proliferation of immune cells, including T cells, B cells, NK cells dendritic cells, monocyte, macrophages, and neutrophils [71–73]. Therefore, we hypothesize that MSCs have strong potential for treating RILI by secreting various paracrine cytokines that regulate inflammatory and fibrotic responses and immunomodulatory actions in injured lung tissue. Interestingly, Chen et al. reported that preactivation of MSCs with TNF-α, IL-1β, and nitric oxide can enhance paracrine effects on radiation-induced injury by a heme oxygenase-1 dependent mechanism [74]. Similarly, Block et al. reported that MSCs can be activated by UV-irradiated fibroblasts to secrete stanniocalcin-1, a peptide hormone that modulates calcium metabolism [75]. The antiprotective effect of stanniocalcin-1 secretion by MSCs was also observed in a coculture system with injured lung cancer epithelial cells, suggesting that the inflammatory environment is probably a key factor in regulating the paracrine responses of MSCs [75]. However, although utilizing the paracrine functions of MSCs to treat RILI shows considerable promise, further investigation of the paracrine-associated mechanisms of MSCs in RILI therapy is still needed.

**Table 1. Summary of soluble paracrine factors of MSC derived secretome for RILI therapy**

| Soluble factors | Species | Role for RILI therapy | References |
|----------------|---------|-----------------------|------------|
| IL1RN          | Murine MSCs | Inhibits IL-1α and IL-1β, reduces TNF-α | [65, 66] |
| PGE2          | Human MSCs | Increases their anti-inflammatory IL-10 production | [43, 52] |
| HGF            | Human MSCs | Reduces TNF-α, IFN-γ, IL-6, TGF-β | [43, 49] |
| SOD3           | Human MSC | Reduces collagen deposition, inflammatory cell infiltration, and oxidative stress | [61] |
| MnSOD          | Human MSCs | Attenuates lung inflammation, ameliorates lung damage, and protects the lung cells from apoptosis | [62] |
| IL1RN          | Murine MSCs | Inhibits IL-1α and IL-1β, and reduces TNF-α | [65, 66] |

**Advantages of Using MSC-Derived Exosomes Compared with MSCs**

In addition to secreting an array of soluble cytokines that could attenuate RILI (Fig. 1), MSCs also release large numbers of extracellular vesicles (EVs) that mediate tissue repair and anti-inflammatory effects in lung pathogenesis [66]. Indeed, exogenously administered MSCs may exert some of their complex paracrine anti-inflammatory, antifibrogenic actions and prorregenerative roles through released EVs [66]. Therefore,
there is growing interest in the possibility of using EVs derived from cultured MSCs as a safe and, effective cell-free therapy [76], especially because of the potential carcinogenic effect of administering MSCs [77]. EVs are typically categorized based on their biogenesis. The 3 main classes of EVs are exosomes, microvesicles and apoptotic bodies [66], all of which are enclosed by a lipid bilayer and which range from 30 to 2,000 nm in diameter depending on the biogenesis pathway [66]. The term “exosome” refers to an endosome-derived subclass of membrane microvesicles with a diameter of 50–100 nm, that are components of the secretome of multiple cell types, including MSCs [66, 78]. Exosomes are important facilitators in cell-to-cell interactions by impacting multiple signalling pathways [66, 78], and their contents include proteins, miRNA and lipids [79]. Compared with MSCs, MSC-derived exosomes present exciting advantages [25]. Firstly, exosomes are vesicles with a lipid bilayer membrane that protects a complex cargo of enzymes, cytokines and genetic material [80]. They can transfer their cargo to target cells due to various proteins present on the vesicle surfaces that have binding affinity for cellular surfaces. Secondly, exosomes can travel freely through blood due to their small size and can easily fuse with cells due to their surface structures [80]. In contrast, after systemic delivery, only a small number of MSCs arrive at the target site, and only a small percentage of those cells can integrate into the tissue and exert their functions for a short time. Thirdly, exosomes do not express MHC I or II antigens whereas MSCs can be induced to express higher levels of MHC II with inflammation [25]. Fourthly, exosomes can be loaded with chemotherapeutics, specific proteins, metabolites, or RNAs including miRNAs and siRNAs [81].

**Modulation of Expression Levels of RILI-Related Inflammatory Cytokines by MSC-Derived Extracellular Vesicles**

RP differs from other pulmonary pneumonitis arising from other causes such as allergic pneumonitis, chemical pneumonitis, or pneumonia with viral, bacterial, fungal, or parasitic origins [9]. Accumulating studies show that RP is a type of inflammatory reaction involving high expression levels of proinflammatory cytokines such as IL-1α, IL-1β, IL-6, and others, which may play a main role in RILI progression and can be regulated by MSC application [23, 26, 33, 35, 49, 82]. However, the immunomodulatory ability of MSCs cannot be sufficiently explained by the effects of only 1 secreted factor [83–85], and therefore it is likely that this ability results from the synergism of multiple factors. MSC-exosome shuttling of multiple immunomodulatory proteins is an ideal pathway for this synergism [86–88], and consistent with this, MSC exosomes can attenuate levels of the proinflammatory cytokines IL-1β, IL-6, TNF-α and induce high levels of the anti-inflammatory IL-10 in vitro [89]. These released cytokines are also closely involved in RILI pathogenesis [33]. Similar anti-inflammatory effects were also reported in other studies of MSC-exosome applications [90–92]. Moreover, Wen et al. showed that both murine and human MSC-derived extracellular vesicles can reverse radiation damage [93]. Blazquez et al. further reported that exosomes derived from human adipose MSCs can inhibit the differentiation and activation of T cells and reduce IFN-γ production by stimulated T cells in vitro [94]. Based on these findings, we hypothesize that MSC exosomes could have therapeutic potential for RILI.

**Modulation of Expression Levels of RILI-Related Inflammatory Cytokines by MSC Release of Exosomal miRNAs**

Changes in miRNAs after radiation have been reported in lung cancer patients undergoing radiotherapy in the clinic and animal studies [95, 96], suggesting that miRNAs may function during the pathologic process of RILI. Information approximately miRNA changes in the lung after radiation will facilitate a better understanding of the mechanism(s) of injury. Indeed, a growing number of studies show that using MSC exosome-shuttled miRNAs can treat multiple inflammatory diseases by regulating levels of the proinflammatory...
The evidence above indicates the therapeutic potential of the MSC paracrine secretome and exosomes for RILI; however, the problems and translational challenges of the MSC secretome and exosomes have to be addressed before the therapies can be routinely applied in RILI patients.

The Tumor-Promoting Effect of MSC-Derived Soluble Factors

Although results from clinical studies using MSCs for the treatment of various lung diseases show that MSC treatment in some patients is safe [103], the carcinogenic potential of MSCs has been the subject of strong controversy for some time [77, 104]. Indeed, in addition to giving rise to cancer themselves, MSCs can also secrete a plethora of paracrine cytokines to promote tumor progression [104, 105]. For example, cell proliferation is a key process of tumor growth in tumor progression, and MSCs can promote this process by releasing IL-6 [106], IL-8 [107], MCP-1 [108], CXCL16 [109], and glutamine [110], by activating the JAK2-STAT3 pathway [106] and AMPK/mTOR-mediated NF-κB signaling [107], and through a β1-integrin-dependent mechanism [111]. Moreover, angiogenesis, as an essential component of tumor growth and survival, can also be promoted by key vasculogenic factors secreted by MSCs, including CXCL1 [112], CXCL8 [112], GDNF [113], VEGF [114], and TGF-β [114]. In addition, tumor cell invasion and migration are further malignant behaviors in tumor progression, and MSCs can promote these behaviors by producing and releasing IL-6 [115], IL-8 [115], CCL5 [116], IL-17B [117], soluble NRG1 [118], β2-microglobulin [119], FGF10 [120], VEGFC [120], MMPs [120], and nitric oxide [121], by activation of NF-κB, STAT3, PI3K/AKT signaling [117, 122], and in part through the Wnt pathway [120]. In addition to promoting tumor progression, MSCs can also elicit drug resistance in tumors by secreting CXCL1 and by activation of the STAT3 pathway [123, 124], and further promote tumor stemness by producing Gremlin-1, BMP2, BMP4, CXCL7, CXCL12, and others [114].

The Tumor-Promoting Effect of MSC-Derived Exosomes

Despite the fact that exosomes do not elicit acute immune rejection and lack the potential to directly form tumors, MSC-derived exosomes are also capable of inducing physiological processes in tumor development, for example, proliferation, angiogenesis, metastasis, and drug resistance. For example, MSC-derived exosomes can promote these processes in gastric cancer cells via activation of ERK, the PKB pathway [125], and Hedgehog signaling [126]. Moreover, MSC-derived exosomes can promote EMT effects via the FGF19-FGFR4 axis in nasopharyngeal carcinoma [127] and by TGF-β1 signaling in lung cancer [128]. In addition, such exosomes can also deliver mir-222/223 or mir-9 to induce drug resistance in tumors [125]. Similarly, Dong et al. showed that MSC-derived EVs can promote lung cancer growth by transferring mir-410, which is probably involved in PTEN downregulation [129]. On the other hand, MSC-derived exosomes are reported to exert proapoptotic functions in hepatoma [130], Kaposi’s sarcoma [130] and ovarian tumors [130],...
suggesting a complex role for MSC-derived exosomes in tumor progression and one that warrants further investigation.

**Hurdles in Clinical Translation**

Compared with the risk of tumor-promoting effect of MSCs, the following major translational challenges should be considered seriously before clinical application of the MSC paracrine secretome and exosomes in the future.

First, according to the European and United States regulatory bodies, acquisition and processing of MSCs need to be in accordance with Good Manufacturing Practices (GMPs), which demand a high level of standardization, regarding the isolation of MSCs, the culture medium and serum for MSCs, and the use of closed-system bioreactors. GMP standards also demand stringent and standardized quality control measures for MSC production with reference to microbiological safety and the absence of any transformation due to genetic instability [77]. In addition, lack of a comparative characterization of murine and human MSCs may also limit the direct translation of preclinical animal model studies to the clinical setting. Another big concern regarding MSC therapy for RILI is perhaps the potential for fibrosis. Yan et al. reported that Flk-1 + MSCs injected into the lung immediately after irradiation could differentiate into functional lung alveolar epithelial cells and induce them to differentiate into myofibrocytes, which then participate in lung fibrosis development [134], possibly because the TGF-β1 level is markedly increased in the middle and later stages after irradiation and mediates the regulation of the fibrosis process through the TGF-β1/SMAD3 pathway [100].

Second, to understand the mechanisms of how cytokines are expressed during RILI and how they modulate the therapeutic effects of stem cells are a significant challenge due to the myriad complex interactions of paracrine factors in the secretome of MSCs. In addition, despite the fact that the secretome of MSCs is normally present in conditioned medium, the components of conditioned medium do not only reflect the secretome because the medium also contains proteins that are released during cell death. Avoiding leakage of intracellular proteins from dead cells is thus a challenge in the careful optimization of the secretome from MSCs. Furthermore, the production and concentration of secreted molecules in quantities sufficient for clinical application may thus be a challenge in the careful optimization of the secretome from MSCs. In addition, despite the fact that the secretome of MSCs is normally present in conditioned medium, the components of conditioned medium do not only reflect the secretome because the medium also contains proteins that are released during cell death. Avoiding leakage of intracellular proteins from dead cells is thus a challenge in the careful optimization of the secretome from MSCs. Furthermore, the production and concentration of secreted molecules in quantities sufficient for clinical application may thus be a challenge in the careful optimization of the secretome from MSCs.

**Table 2. Anti-inflammatory or antifibrotic effects of top 18 abundant miRNAs in umbilical cord MSCs-derived exosomes**

| MicroRNA | Targets | Effects on inflammation or fibrosis | References |
|----------|---------|-----------------------------------|------------|
| miR-21-5p | PTEN, PDCD4 | Dampens NF-κB/TNFα signaling, induces IL-10 expression | [143] |
| miR-125b-5p | Smad2 | Inhibits TGF-β2/Smad2 pathway | [100] |
| miR-23a-3p | TGFβ2 | Inhibits TGF-β2/Smad2 pathway | [100] |
| miR-100-5p | mTOR | Modulates the expression of IL-6 | [144, 145] |
| Let-7f-5p | IL-6 | Targets IL6 to inhibit inflammation | [146] |
| Let-7a-5p | LIN28B, TGFBR1 | Targets Lin28B to regulate IL6 and NF-κB pathway | [147–149] |
| miR-145-5p | Smad3 | Negatively regulates proinflammatory cytokine release from in COPD by targeting SMAD3 | [150] |
| miR-1260b | Smad4 | Regulates TGF-β pathway via targeting Smad4 | [151, 152] |
| miR-1260a | COL1A1 | Targets the fibrosis marker COL1A1 | [153, 154] |
| miR-199a-3p | COX2 | Targets COX2 to block TNF-α pathway | [149, 155] |
| miR-16-5p | Smad3 | Decreases IL-1β, TNF-α, and NF-κB | [156, 157] |
| miR-195-5p | Dll1 | Inhibits notch-induced IL-22 secretion | [158, 159] |
| miR-191-5p | STX3 | Inhibits secretion of IL-1α, IL-1β, IL-12β, and CCL4 via targeting STX3 | [160, 161] |
| miR-221-3p | SDF1 | Prevents IL-1β-induced ECM degradation | [162] |
| miR-223-3p | IRF-2, ICAM-1 | Inhibits inflammation via targeting IRF-2, ICAM-1 | [163, 164] |
| miR-23b-3p | PTEN | Inhibits PTEN to promote the phosphorylation of Akt which leads to a decrease in proinflammatory cytokine production | [165, 166] |
| miR-3-120-5p | Hsc70 | Inhibits Hsc70-triggered activation of TLR signaling and inflammatory cytokine production via target Hsc70 | [167, 168] |
| miR-214-3p | EZH1, EZH2 | Prevents fibrosis-associated genes in myofibroblasts via targeting EZH1 and EZH2 | [169] |
administration are also challenging. Other limitations of secretome therapy include tissue transport, pharmacokinetics, and protein stability.

Third, as with the use of MSCs, the defined and standardized methods used to isolate and identify exosomes will also be required, according to the International Society of Extracellular Vesicles [135]. Thus, a universally accepted protocol for exosome isolation, large-scale GMP production guidance, as well as validated methods for quantifying and evaluating the potency of exosomes are lacking. According to preclinical studies, the amount of MSC EVs required to produce the equivalent effect of MSCs in lung injury is generally 10 times higher [25]. Therefore, if the average dose of MSCs is 10 x 10^6 cells per kilogram per body weight, the number of MSCs required to generate enough exosomes may be greater than 100 x 10^6 of MSC per kilogram, which may make the production costs prohibitive. In addition, expanding big batches of MSCs for exosome production will impact the costs of derivation, testing, and validation, because the biological properties of MSCs may become altered with repeated passages [25]. Although a potential approach to significantly increasing extracellular vesicle production could be the use of bioreactor systems to culture MSCs, different bioreactor culture conditions may impact the content and therapeutic efficacy of EVs, including the build-up of metabolic byproducts, pH balance, hydrodynamic shear stress, and oxygen supply [25]. The very significant barriers above underline the need for caution on rapid clinical translation. Although clinical effects of using MSC exosomes have been explored in phase I and II trials in lung diseases [136], the latent side effects, based on the recipients’ long-term follow-up, was unclear. In addition, the uptake mechanisms for exosomal miRNAs and the mechanisms that regulate incorporation of a particular miRNA into exosomes are still unclear, so the best methods for confirming their safety and proving their efficacy in vitro and especially in vivo still need to be resolved. Finally, other issues related to clinical application of these therapies, including ethical, legal, technical and regulatory concerns, are also challenging.

**SUMMARY AND FUTURE PERSPECTIVES**

RILI is a major limiting factor in the application of thoracic radiation and a major obstacle to the use of advanced dose escalation modalities and ablative hypofractionation radiotherapy regimens. Therefore, developing alternative strategies to protect the lungs from RILI is essential. However, there are still existing drawbacks in the application of various therapeutic drugs for RILI therapy. MSCs, as an immunomodulatory and regenerative tool, exhibit considerable promise for targeting RILI pathogenesis by secreting paracrine cytokines, as demonstrated in a growing number of studies. However, tumor-promoting features of the MSC paracrine secretome may limit the translational application of MSCs for clinical RILI patients. Indeed, it has been reported that MSCs may possess a distinct tropism to tumors after systemic administration [137, 138]. And some studies have demonstrated that MSCs that are cultured for a long-term may exhibit some neoplastic transformation [139, 140]. The progression of existing tumors may be problematic due to direct effect on the tumor or surrounding stroma as a result of reducing inflammation and promoting tumor evasion from the immune system. Thus, the limitations of tumorigenic potential of MSCs in clinical trials should be also considered. Furthermore, studies should focus on more clearly identifying factors responsible for the therapeutic effects of MSCs. These efforts will help to develop more effective protein-based conditioning approaches. Modification of the secretion profile to augment the therapeutic effects of the secretome may be achieved via physical, physiological, and pharmaceutical preconditioning of stem cells including hypoxia induction, treatment with disease-specific drugs, small molecules, specific growth factors/cytokines, and cellular reprogramming/genetic manipulation strategies.

Compared with MSCs, although MSC-derived exosomes exhibit many advantages for treating lung diseases [25], the promoting and proapoptotic role of MSC-derived exosomes on tumor progression raises controversy with reference to their suitability for clinical translation. Fortunately, it was recently reported that miRNAs are transported by exosomes in lung disease [136], suggesting that, instead of native exosomes, exosomes modified by the expression of different miRNAs will be a promising alternative for RILI therapy. In particular, taking advantage of miRNAs that can inhibit both cancer and inflammation will be a better alternative for RILI therapy based on MSC-derived exosome cargo.

In addition, MSC-derived exosomes contain not only miRNA but also lipids [79] and long noncoding RNAs, which regulate multiple signaling pathways related to inflammation [141]. Moreover, immune cells can interact with various classes of lipids to regulate the plasticity of macrophages and T lymphocytes [142]. Whether MSC-derived exosomes can attenuate RILI via shuttled long noncoding RNAs, lipids, or both is unknown. Thus, the progress made so far on the potential of MSCs in RILI therapy suggests that the MSC-derived secretome and exosomes function in RILI through a variety of mechanisms but that further research is needed to understand their potential.

**AUTHOR CONTRIBUTIONS**

S.X.: manuscript preparation, financial support; C.L.: literature search; S.X. and H.L.J.: conception and design, manuscript revision, final approval of manuscript.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

The authors indicated no potential conflicts of interest.

**REFERENCES**

1 Jeremic B, Fidarova E, Sharma V et al. The International Atomic Energy Agency (IAEA) randomized trial of palliative treatment of incurable locally advanced non small cell lung cancer (NSCLC) using radiotherapy (RT) and chemotherapy (CHT) in limited resource setting. Radiother Oncol 2015;116:21–26.

2 Graves PR, Siddiqui F, Anscher MS et al. Radiation pulmonary toxicity: From mechanisms to management. Semin Radiat Oncol 2010;20:201–207.

3 Marks LB, Yu X, Vujaskovic Z et al. Radiation-induced lung injury. Semin Radiat Oncol 2003;13:333–345.

4 Marks LB, Bentzen SM, Deasy JO et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76:76–76.

5 Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 2005;63:5–24.

6 Epperly MW, Guo H, Gretton JE et al. Bone marrow origin of myofibroblasts in...
irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29:213–224.
27 Takeda A, Kunieda E, Takeda T et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008;70:1057–1065.
28 Castellino RA, Glattstein E, Turbow MM et al. Latent radiation injury of lungs or heart activated by steroid withdrawal. Ann Intern Med 1974;80:593–599.
29 Rajan Radha R, Chandrasekharan G. Pulmonary injury associated with radiation therapy—Assessment, complications and therapeutic targets. Biomed Pharmacother 2017;89:1092–1104.
30 Devine A, Marigol L. Potential of amifostine for chemoradiotherapy and radiotherapy-associated toxicity reduction in advanced NSCLC: A meta-analysis. Anticancer Res 2016;36:5–12.
31 Arora R, Gupta D, Chawla R et al. Radioprotection by plant products: Present status and future prospects. Phytother Res 2005;19:1–22.
32 Srinivasan M, Sudheer AR, Pillai KR et al. Lycopene as a natural protector against gamma-radiation induced DNA damage, lipid peroxidation and antioxidant status in primary culture of isolated rat hepatocytes in vitro. Biochim Biophys Acta 2007;1770:659–665.
33 Liu Z, Lei X, Li X et al. Toll-like receptors and radiation protection. Eur Rev Med Pharmacol Sci 2018;22:31–39.
34 Ghafouri F, Marks LB, Vujaskovic Z et al. Radiation-induced lung injury assessment, management, and prevention. Oncology 2008;72:37–47.
35 Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208:1339–1350.
36 Horie S, Laffey JG. Recent insights: Mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome. Anesthesiology 2016;5:238–240.
37 Penfornis P, Pochampally R. Isolation and expansion of mesenchymal stem cells/multipotent mesenchymal stromal cells from human bone marrow. Methods Mol Biol 2011;698:11–21.
38 Rasini V, Dominici M, Kluba T et al. Mesenchymal stromal/stem cells markers in the human bone marrow. Cytotherapy 2013;15:292–306.
39 Lindner U, Kramer J, Rohwedel J et al. Mesenchymal stem or stromal cells: Toward a better understanding of their biology? Transfus Med Hemother 2010;37:75–83.
40 Jacobs SA, Roobrouck VD, Verfaille CM et al. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol 2013;91:32–39.
41 Golemovic M, Skiffl M, Cepulic BG. Mesenchymal stem cells: Immunomodulatory properties and clinical application. Lijec Vjesn 2012;134:42–49.
42 Singh A, Singh A, Sen D. Mesenchymal stem cells in cardiac regeneration: A detailed progress report of the last 6 years (2010–2015). Stem Cell Res Ther 2016;7:82–107.
43 Jiang X, Jiang X, Qu C et al. Intravenous delivery of adipose-derived mesenchymal stromal cells attenuates acute radiation-induced lung injury in rats. Cytotherapy 2015;17:560–570.
44 Chinnadurai R, Ng S, Velu V et al. Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease. World J Gastroenterol 2015;21:4779–4787.
45 Monsel A, Zhu YG, Gudapati V et al. Mesenchymal stem cell derived secretional and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opin Biol Ther 2016;16:859–871.
46 Xue J, Li X, Lu Y et al. Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. Mol Ther 2013;21:456–465.
47 D’Agostino B, Sullo N, Siniscalco D et al. Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease. Expert Opin Biol Ther 2010;10:681–689.
48 Weiss DJ, Kolls JK, Ortiz LA et al. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008;5:637–667.
49 Riley PA. Free radicals in biology: Oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994;65:27–33.
50 Ding NH, Li JJ, Sun LQ. Molecular mechanisms and treatment of radiation-induced lung fibrosis. Curr Drug Targets 2013;14:1347–1356.
51 Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: Therapeutic implications. Curr Med Chem 2009;16:130–143.
52 Johnston CJ, Williams JP, Okunieff P et al. Radiation-induced pulmonary fibrosis: Examination of chemokine and chemokine receptor families. Radiat Res 2002;157:256–265.
53 Xia C, Chang P, Zhang Y et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells on radiation-induced lung injury. Oncol Rep 2016;35:731–738.
54 Mavis AT, Toupet K, Bony C et al. Antibiotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis. Arthritis Rheumatol 2016;68:1013–1025.
55 Oh JY, Ko JH, Lee HJ et al. Mesenchymal stem/stromal cells inhibit the NLPR3 inflammasome by decreasing mitochondrial reactive oxygen species. Stem Cells 2014;32:1553–1563.
56 Li J, Li D, Liu X et al. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm 2012;9:33–44.
57 Klein D, Schmetter A, Imsak R et al. Therapy with multipotent mesenchymal stromal cells protects lungs from radiation-induced injury and reduces the risk of lung metastasis. Antioxid Redox Signal 2016;24:53–69.
58 Martin M, Lefaix JL, Pinton P et al. Temporal modulation of TGF-beta1 and beta-3 in reactive oxygen species. Stem Cells 2014;32:353–360.
59 Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: A master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000;47:277–290.
60 Rodemann HP, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiother Oncol 1995;35:83–90.
61 Hu Y, Peng J, Feng D et al. Role of extracellular signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-beta1-induced alpha smooth muscle actin expression in human fetal liver fibroblasts in vitro. Lung 2006;184:33–42.
62 Zhang C, Zhu Y, Zhang Y et al. Therapeutic potential of umbilical cord mesenchymal stem cells for inhibiting myofibroblastic differentiation of irradiated human lung fibroblasts. Tohoku J Exp Med 2015;236:209–217.
63 Dong LH, Jiang YY, Liu YJ et al. The anti-fibrotic effects of mesenchymal stem cells on irradiated lungs via stimulating endogenous secretion of HGF and PGE2. Sci Rep 2015;5:8713–8723.
64 Liu J, Pan G, Liang T et al. HGF/C-Met signaling mediated mesenchymal stem cell-induced liver recovery in intestinal ischemia reperfusion model. Int J Med Sci 2014;11:626–633.
65 Kearns-Jonker M, Dai W, Gunthart M et al. Genetically engineered mesenchymal stem cells influence gene expression in donor cardiomyocytes and the recipient heart. J Stem Cell Res Ther 2012;11:1–20.
66 Shukla MN, Rose JL, Ray R et al. Hepatocyte growth factor inhibits epithelial to myofibroblastic transition in lung cells via Smad7. Am J Respir Cell Mol Biol 2009;40:643–653.
67 Mizuno S, Matsumoto K, Li MY et al. HGF reduces advancing lung fibrosis in mice: A potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005;19:580–582.
68 Singh S, Saraila L, Ekington PT et al. Regulation of matrix metalloproteinase-1, −3, and −9 in Mycobacterium tuberculosis-dependent respiratory networks by the rapsyacin-sensitive P43/P70(S6K) cascade. FASEB J 2014;28:85–93.
69 Wang H, Yang YF, Zhao L et al. Hepatocyte growth factor gene-modified mesenchymal stem cells reduce radiation-induced lung injury. Hum Gene Ther 2013;24:343–353.
70 Mattiloubian M, Lo CG, Cinagno M et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355–360.
71 Sanna MG, Wang SK, Gonzalez-Cabrera PJ et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2006;2:434–441.
72 Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42–49.
73 Okunishi K, Sisson TH, Huang SK et al. Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. J Biol Chem 2011;286:32231–32243.
74 Moore BB, Peters-Golden M, Christensen PJ et al. Alveolar epithelial cell
inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2. Am J Physiol Lung Cell Mol Physiol 2003;284:343–352.

55 Walker NM, Badri LN, Wadhwa A et al. Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Respir Crit Care Med 2012;185:77–84.

56 Thomas PE, Peters-Golden M, White ES et al. PC2D inhibition of TGF-beta1-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling. Am J Physiol Lung Cell Mol Physiol 2007;293:417–428.

57 White ES, Atras RG, Dickie EG et al. Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTE2 activity. Am J Physiol Lung Cell Mol Biol 2005;32:135–141.

58 Bauman KA, Wettlaufer SH, Okunishi K et al. The antibiofilm effects of plasmaminogen activation occur via prostaglandin D2-dependent synthesis of human and mice. J Clin Invest 2010;120:1950–1960.

59 Kost OA, Beznos OV, Davydova NG et al. Superoxide dismutase 1 nanoezyme for treatment of eye inflammation. Oxid Med Cell Longev 2015;5:1–13.

60 Perich J, Wiesemann A et al. Mesenchymal stem cell therapy protects lungs from radiation-induced endothelial cell loss by restoring superoxide dismutase 1 expression. Antioxid Redox Signal 2017;26:563–582.

61 Wei L, Zhang J, Yang ZL et al. Extracellular superoxide dismutase increased the therapeutic potential of human mesenchymal stromal cells in radiation pulmonary fibrosis. Cytotherapy 2017;19:586–602.

62 Chen HK, Xiang H, Xu WH et al. Malaysian superoxide dismutase gene-modified mesenchymal stem cells attenuate acute radiation-induced lung injury. Hum Gene Ther 2017;28:523–532.

63 Halliwell B. Free radicals and antioxidants: Updating a personal view. Nutr Rev 2012;70:257–265.

64 Kim J, Kil IS, Seok YM et al. Orchietectomy induces post-ischemic paracrine-stress and ischemia-reperfusion injury in mice. A role for manganese superoxide dismutase. J Biol Chem 2006;281:20349–20356.

65 Johnston CJ, Piedboeuf B, Rubin P et al. Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat Res 1996;145:762–767.

66 Ortiz LA, Dutreil M, Fatmann C et al. Interleukin-1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007;104:11002–11007.

67 Haase MG, Klawitter A, Geyer P et al. Sustained elevation of NF-kappaB DNA binding activity in radiation-induced lung damage in rats. Int J Radiat Biol 2003;79:863–877.

68 Yagi H, Soto-Gutierrez A, Navarro-Alvarez N et al. Reactive bone marrow stromal cells attenuate systemic inflammation via tSNF1R1. Mol Ther 2010;18:1857–1864.

69 Ishikuma H, Miyazono K. TGFbeta signalling: A complex web in cancer progression. Nat Rev Cancer 2010;10:415–424.
infection. **Stem Cells Translational Medicine** 2016;5:1190–1203.

103 Geiger S, Hirsch D, Hermann FG. Cell therapies for lung disease. Eur Respir Rev 2017;26:1–7.

104 Rhee KJ, Lee JI, Eom YW. Mesenchymal stem cell-mediated effects of tumor support or suppression. Int J Mol Sci 2015;16:30005–30033.

105 Zou JS, Johnson CL, Soeder Y et al. Caveats of mesenchymal stem cell therapy in solid organ transplantation. Transpl Int 2015; 28:1–9.

106 Wei HI, Zeng R, Lu JH et al. Adipose-derived stem cells promote tumor initiation and accelerate tumor growth by interleukin-6 production. Oncotarget 2015;6:7773–7776.

107 W Xu, SB, Liu Y, Wang GH et al. Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-kappaB activation. Sci Rep 2016;6:1–12.

108 Jia KH, Du Y, Mao D et al. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages. Oncotarget 2015;6:26018–26028.

109 Takiguchi G, Nishita M, Kurita K et al. Wnt5a-Ror2 signaling in mesenchymal stem cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 axis. Cancer Sci 2016;107:290–297.

110 Tang K, Hu L, Ma J et al. Brief report: Human mesenchymal stem-like cells facilitate floating tumorigenic cell growth via glutamine-amarone cycle. Stem Cells 2015; 33:2877–2884.

111 Wiedmer D, Lutzkendorf J, Caysa H et al. Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a beta1-integrin-dependent mechanism. Int J Cancer 2016;138:964–975.

112 Wang Y, Liu J, Jiang Q et al. Human adipose-derived mesenchymal stem cell secreted CXCL1 and CXCL8 facilitate breast tumor growth by promoting angiogenesis. Stem Cells 2015;33:2060–2070.

113 Zhong Z, Gu H, Peng J et al. GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis. Oncotarget 2016;7:36829–36841.

114 Ghaderi A, Abtahi S. Mesenchymal stem cells: Miraculous healers or dormant killers? Stem Cell Rev 2018;14:722–733.

115 Ma F, Chen D, Chen F et al. Human umbilical cord mesenchymal stem cells promote breast cancer metastasis by interleukin-8- and interleukin-6-dependent induction of CD44(+)/CD24(–) cells. Cell Transplant 2015; 24:2585–2599.

116 Zhong W, Tong Y, Li Y et al. Mesenchymal stem cells in inflammatory microenvironment potently promote metastatic growth of cholangiocarcinoma via activating Akt/NF-kappaB signaling by paracrine CCL5. Oncotarget 2017;8:73693–73704.

117 Bie Q, Zhang B, Sun C et al. IL-17 activates mesenchymal stem cells to enhance proliferation and migration of gastric cancer cells. Oncotarget 2017;8:18914–18923.

118 De Boeck A, Pauwels P, Hensen K et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neutregulin 1/HER3 signalling. Gut 2015;62:550–560.
upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer 2014;110:1645–1654.

152 Yang G, Yang X. Smad4-mediated TGF-beta signaling in tumorigenesis. Int J Biol Sci 2010;6:1–8.

153 Li BB, Li DL, Chen C et al. Potentials of the elevated circulating miR-185 level as a biomarker for early diagnosis of HBV-related liver fibrosis. Sci Rep 2016;6:34157–34156.

154 Cheuk BL, Cheng SW. Identification and characterization of microRNAs in vascular smooth muscle cells from patients with abdominal aortic aneurysms. J Vasc Surg 2014;59:202–209.

155 Williams KC, Renthal NE, Gerard RD et al. The microRNA (miR)-199a/214 cluster mediates opposing effects of progesterone and estrogen on uterine contractility during pregnancy and labor. Mol Endocrinol 2012;26:1857–1867.

156 Ye EA, Liu L, Jiang Y et al. MiR-15a/16 reduces retinal leukostasis through decreased pro-inflammatory signaling. J Neuroinflammation 2016;13:305–314.

157 Li L, Jia J, Liu X et al. MicroRNA-16-5p controls development of osteoarthritis by targeting SMAD3 in chondrocytes. Curr Pharm Des 2015;21:5160–5167.

158 Xu F, Zhu Y, He Q et al. Identification of microRNA-regulated pathways using an integration of microRNA-miRNA microarray and bioinformatics analysis in CD34+ cells of myelodysplastic syndromes. Sci Rep 2016;6:32232–32242.

159 Wei X, Wang JP, Hao CQ et al. Notch signaling contributes to liver inflammation by regulation of interleukin-22-producing cells in hepatitis B virus infection. Front Cell Infect Microbiol 2016;6:132–142.

160 Mendes-Silva AP, Pereira KS, Tolentino-Araujo GT et al. Shared biologic pathways between alzheimer disease and major depression: A systematic review of microRNA expression studies. Am J Geriatr Psychiatry 2016;24:903–912.

161 Naegelein I, Plancon S, Nicot N et al. An essential role of syntaxin 3 protein for granule exocytosis and secretion of IL-1alpha, IL-1beta, IL-12b, and CCL4 from differentiated HL-60 cells. J Leukoc Biol 2015;97:557–571.

162 Zheng X, Zhao FC, Pang Y et al. Downregulation of miR-221-3p contributes to IL-1beta-induced cartilage degradation by directly targeting the SDF1/CXCR4 signaling pathway. J Mol Med 2017;95:615–627.

163 Duan M, Yao H, Hu G et al. HIV Tat induces expression of ICAM-1 in HEVUCs: Implications for miR-221/222 in HIV-associated cardiomyopathy. PLoS One 2013;8:1–11.

164 Corsten M, Heggiesmont W, Papageorgiou AP et al. The microRNA-221/222 cluster balances the antiviral and inflammatory response in viral myocarditis. Eur Heart J 2015;36:2909–2919.

165 Zaman MS, Thamminana S, Shahryari V et al. Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One 2012;7:1–10.

166 Kalantari P, Harandi OF, Agarwal S et al. miR-718 represses proinflammatory cytokine production through targeting phosphatase and tensin homolog (PTEN). J Biol Chem 2017;292:5634–5644.

167 Scott H, Howarth J, Lee YB et al. MiR-3120 is a mirror microRNA that targets heat shock cognate protein 70 and auxilin messenger RNAs and regulates clathrin vesicle uncoating. J Biol Chem 2012;287:14726–14733.

168 Imamura Y, Wang PL. Salivary histatin 3 inhibits heat shock cognate protein 70 and auxilin messenger RNAs and regulates clathrin vesicle uncoating. J Biol Chem 2012;287:14726–14733.

169 Zhu WS, Tang CM, Xiao Z et al. Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts. Oncotarget 2016;7:78331–78342.